The North America qPCR Reagents Market was valued at USD 780 Million in 2025 and is projected to reach USD 1,530 Million by 2035, registering a CAGR of 6.3% during 2024–2035. This growth is driven by advancements in molecular diagnostics, the increasing prevalence of infectious and chronic diseases, and the demand for high-throughput diagnostic solutions.
The economic impact of tariffs on "North America qPCR Reagents Market".
Market Growth Drivers
Expansion of Personalized Medicine: The increasing focus on precision medicine has significantly driven the adoption of qPCR reagents. Leading companies such as Thermo Fisher Scientific provide advanced reagent kits that enable the detection of genetic variations and biomarkers, enhancing the accuracy of diagnostics and therapy selection. The growing trend of gene-based treatments and companion diagnostics is expected to further contribute to market growth, as healthcare providers seek robust, high-sensitivity tools for clinical decision-making.
Surge in Infectious Disease Testing: The recent rise in infectious diseases, including the emergence of new variants of viruses like SARS-CoV-2, has fueled the demand for rapid and reliable molecular diagnostics. Companies such as Bio-Rad Laboratories have developed and launched new qPCR reagent solutions to support large-scale testing and surveillance. The reliability and quick turnaround of qPCR tests have made them a preferred choice in both public health and hospital-based settings across North America.
Market Trends
Automation and High-Throughput Solutions: There is an increasing trend towards the automation of qPCR workflows and integration with high-throughput platforms. Companies such as Agilent Technologies have introduced automated liquid handling systems compatible with their qPCR reagents, enabling laboratories to enhance productivity and minimize human errors. This trend is gaining traction in clinical diagnostic labs and research institutions focused on large-scale genomics projects.
Development of Multiplex Assays: The market is witnessing robust innovation in multiplex qPCR assays, which allow simultaneous detection of multiple targets in a single run. Firms like Qiagen are leading the way, offering multiplex reagent kits that reduce reagent cost and time while improving the efficiency of research and diagnostic applications. This trend is particularly significant in oncology and infectious disease panels, where comprehensive results are crucial for patient management.
Market Opportunity
Emergence of Point-of-Care qPCR Platforms: Increased investments in the development of compact, user-friendly qPCR systems, such as the BioFire FilmArray, present significant opportunities for market players. These point-of-care solutions could enable rapid, decentralized molecular testing in clinics and remote settings, broadening market reach.
Rising Genomics Research Funding: Growing public and private funding for genomic research in North America is expected to boost the demand for advanced qPCR reagents. Strategic collaborations between academic institutions and leading companies like Roche Diagnostics are paving the way for novel applications and workflow improvements in genomics and precision health.
North America qPCR Reagents Market Revenue (USD Million), 2020-2035
The revenue chart demonstrates consistent growth in the North America qPCR Reagents Market over the 2020–2035 period. Starting at USD 470 Million in 2020, the market showed moderate growth each year, reaching USD 780 Million in 2025, fueled by increased adoption of qPCR technology in both clinical and research settings. Post-2025, the momentum is expected to accelerate, driven by expanding applications and technological advancements, culminating at USD 1,530 Million by 2035. The compound annual growth rate (CAGR) for this period is estimated at 6.3%, highlighting strong market potential and investor interest.
North America qPCR Reagents Market Share by Regions (%), 2025
In 2025, the United States accounted for the largest share of the North America qPCR Reagents Market, making up 70% of overall revenues due to its advanced healthcare infrastructure and strong presence of leading life science companies. Canada follows with a 18% share, driven by progressive diagnostic adoption in research and clinical settings. Mexico holds 8%, attributed to its growing investments in healthcare technology, while the 'Rest of North America' including the Caribbean holds a 4% share. The pie chart illustrates the dominant market position of the United States and the expansion potential in Canada and Mexico.
Recent Developments
In May 2024, Thermo Fisher Scientific unveiled its new Invitrogen SuperScript IV qPCR Master Mix, optimized for faster reaction times and improved inhibitor tolerance, directly addressing clinical laboratory needs for rapid turnaround during high-throughput COVID-19 and respiratory virus testing seasons.
In March 2024, Qiagen announced a strategic collaboration with the Mayo Clinic to develop next-generation multiplex qPCR panels aimed at early cancer detection. The kits leverage proprietary chemistry developments to identify multiple cancer biomarkers in a single reaction, aiming to increase the breadth and sensitivity of diagnostics in North American hospitals.
In February 2024, Bio-Rad Laboratories launched its EPIQ qPCR Reagent kit line, which boasts improved accuracy in gene expression quantification for research applications. The launch was accompanied by published validation data, underlining its utility in oncology and immunology studies, and reinforcing Bio-Rad’s leadership in the reagent innovation segment.
Press Releases